5/9/2023 0 Comments Fast by Lola FinnPaul joined the staff at Buckingham as a Professorial Research Fellow in 2013, a joint appointment between the Clore Laboratory and Applied Computing Department. In 2004 Paul moved to InhibOx, a spin-out company from the Chemistry Department of the University of Oxford focused on computer-aided drug design. Following this acquisition Paul became group director of R&D and was responsible for TopoTarget’s extremely successful HDAC inhibitor programme which led to the discovery and development of Beleodaq™, which was granted approval for the treatment of relapsed or refractory PTCL by the FDA in July 2014. In 1998, Paul joined Prolifix, a UK biotechnology company which was acquired in 2002 by TopoTarget, a listed drug development company focused on oncology. In 1990, he moved to Pfizer’s computational chemistry group where he was responsible for developing Pfizer’s in-house approach to virtual screening. Paul completed his undergraduate biochemistry degree at St Peter’s College, Oxford in 1981 and holds a PhD from Manchester University (1985) on the prediction of protein structure by theoretical methods.īetween 19, Paul worked as a scientist in the computational chemistry group at SmithKline Beecham, where he focused on the discovery of novel antibiotic agents.
0 Comments
Leave a Reply. |